Because all the FDA has said is that they can refile the application.
They have done this twice in the past. It sounds like the FDA may now be ok with the potency, but have they changed their minds on needing further evidence?
More specifics would be nice.
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-26
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.025(2.29%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.13 | $1.05 | $8.152M | 7.517M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 69963 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 73154 | 3 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.07 |
Change
-0.025 ( 2.84 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.13 | $1.05 | 1873215 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| MSB (ASX) Chart |